Myasthenia gravis (AChR) – advice Eculizumab treatment

This protocol has been in effect since April 1, 2022, for adults receiving treatment for refractory generalized myasthenia gravis (gMG). It applies to patients who test positive for acetylcholine receptor (AChR) antibodies and have been positively assessed by the indication committee.

Requesting a Treatment Indication
A treatment indication for a patient with AChR(+) MG can be submitted to the committee. A request must include:

1. A recent letter providing an overview of the clinical presentation, additional examinations performed, and previous treatments, including their effects and any side effects.
2. A fully completed checklist with an overview of the start criteria (see guideline).

The committee will review the complete package and will inform the applicant of its decision within four weeks.

Contact person:
Mw. Saskia Strijk, secretary Neurology, LUMC
Postbus 9600, 2300 RC Leiden
Email: C.B.A.Strijk@lumc.nl
Tel: 071-5262197

The commission consists of:
Prof. dr. Jan JGM Verschuuren, neurologist, LUMC (chair)
Dr. Anneke van der Kooi, neurologist, UMC Amsterdam
Dr. Janneke Hoeymakers, neurologist, MUMC+
Dr. Maarten Titulaer, neurologist, ErasmusMC
Dr. Nicol Voermans, neurologist, Radboudumc